MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features

[1]  S. Richard,et al.  [Hereditary kidney cancers: The pathologist's view in 2020]. , 2020, Annales de pathologie.

[2]  V. Matveev,et al.  Case of Hereditary Papillary Renal Cell Carcinoma Type I in a Patient With a Germline MET Mutation in Russia , 2020, Frontiers in Oncology.

[3]  W. Linehan,et al.  Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. , 2019, European urology.

[4]  Chaofu Wang,et al.  Biphasic squamoid alveolar renal carcinoma with positive CD57 expression: A clinicopathologic study of three cases , 2019, Pathology international.

[5]  T. Choueiri,et al.  Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. , 2019, The Lancet. Oncology.

[6]  San-Gang Wu,et al.  21-Gene Recurrence Score Assay and Outcomes of Adjuvant Radiotherapy in Elderly Women With Early-Stage Breast Cancer After Breast-Conserving Surgery , 2019, Front. Oncol..

[7]  G. Vassal,et al.  Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review , 2018, BMC Cancer.

[8]  E. Jonasch,et al.  Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. , 2018, European journal of cancer.

[9]  N. Rioux-Leclercq,et al.  Biphasic papillary renal cell carcinoma is a rare morphological variant with frequent multifocality: a study of 28 cases , 2018, Histopathology.

[10]  S. Suster,et al.  High-grade renal cell carcinoma with emperipolesis: Clinicopathological, immunohistochemical and molecular-genetic analysis of 14 cases. , 2018, Histology and histopathology.

[11]  J. Šufliarský,et al.  Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. , 2017, European journal of cancer.

[12]  R. Alaghehbandan,et al.  Chromosomal numerical aberration pattern in papillary renal cell carcinoma: Review article. , 2017, Annals of Diagnostic Pathology.

[13]  D. Suárez-Vilela,et al.  The Squamoid Cells in Biphasic Squamoid Alveolar Renal Carcinoma Present Cytophagocytosis (Not Emperipolesis) of Apoptotic Neutrophilic Granulocytes. , 2017, The American journal of surgical pathology.

[14]  S. Signoretti,et al.  Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression , 2017, Oncotarget.

[15]  H. Joensuu,et al.  Correlation of c‐Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib , 2017, Clinical genitourinary cancer.

[16]  S. Richard,et al.  Biphasic Squamoid Alveolar Renal Cell Carcinoma: 2 Cases in a Family Supporting a Continuous Spectrum With Papillary Type I Renal Cell Carcinoma. , 2017, The American journal of surgical pathology.

[17]  T. Powles,et al.  Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Troxell,et al.  Renal cell carcinoma in kidney allografts: histologic types, including biphasic papillary carcinoma. , 2016, Human pathology.

[19]  B. Krušlin,et al.  Solid papillary renal cell carcinoma: clinicopathologic, morphologic, and immunohistochemical analysis of 10 cases and review of the literature. , 2016, Annals of diagnostic pathology.

[20]  A. Agaimy,et al.  Biphasic Squamoid Alveolar Renal Cell Carcinoma: A Distinctive Subtype of Papillary Renal Cell Carcinoma? , 2016, The American journal of surgical pathology.

[21]  J. López.  Case Report: Multifocal biphasic squamoid alveolar renal cell carcinoma , 2016, F1000Research.

[22]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. , 2016, The New England journal of medicine.

[23]  Haiying Liang,et al.  Preliminary Genomic Characterization of Ten Hardwood Tree Species from Multiplexed Low Coverage Whole Genome Sequencing , 2015, PloS one.

[24]  Yanying Shen,et al.  Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients , 2015, PloS one.

[25]  Lisa N Kinch,et al.  Spectrum of diverse genomic alterations define non–clear cell renal carcinoma subtypes , 2014, Nature Genetics.

[26]  D. Grignon,et al.  Clear cell renal cell carcinoma with a syncytial-type multinucleated giant tumor cell component: implications for differential diagnosis. , 2014, Human pathology.

[27]  N. Rioux-Leclercq,et al.  MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array , 2014, Clinical Cancer Research.

[28]  Jin Zhang,et al.  Oncocytic papillary renal cell carcinoma: a clinicopathological study emphasizing distinct morphology, extended immunohistochemical profile and cytogenetic features. , 2013, International journal of clinical and experimental pathology.

[29]  C. Magi-Galluzzi,et al.  Metanephric adenoma and solid variant of papillary renal cell carcinoma: common and distinctive features , 2013, Histopathology.

[30]  O. Hes,et al.  Biphasic alveolosquamoid renal carcinoma: a histomorphological, immunohistochemical, molecular genetic, and ultrastructural study of a distinctive morphologic variant of renal cell carcinoma. , 2012, Annals of diagnostic pathology.

[31]  Amnon Zisman,et al.  Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma , 2009, Clinical Cancer Research.

[32]  C. Elie,et al.  Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. , 2007, Urology.

[33]  Y. Ko,et al.  MET Expression in Sporadic Renal Cell Carcinomas , 2006, Journal of Korean medical science.

[34]  F. McGovern,et al.  Renal-cell carcinoma. , 2005, The New England journal of medicine.

[35]  Liang Cheng,et al.  Gains of Chromosomes 7, 17, 12, 16, and 20 and Loss of Y Occur Early in the Evolution of Papillary Renal Cell Neoplasia: A Fluorescent In Situ Hybridization Study , 2003, Modern Pathology.

[36]  W. Marston Linehan,et al.  Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas , 1998, Nature Genetics.

[37]  Francesco Pagano,et al.  Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours , 1998, Oncogene.

[38]  A. Renshaw,et al.  Solid variants of papillary (chromophil) renal cell carcinoma: clinicopathologic and genetic features. , 1997, The American journal of surgical pathology.

[39]  S. Scherer,et al.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[40]  P. Stephens,et al.  Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. , 2018, European urology.

[41]  Nidhi Gupta,et al.  Emperipolesis, entosis and cell cannibalism: Demystifying the cloud , 2017, Journal of oral and maxillofacial pathology : JOMFP.

[42]  Jonathan I. Epstein,et al.  WHO Classification of of Tumours of the Urinary System and Male Genital Organs , 2016 .

[43]  J. López.  Case Report: Multifocal biphasic squamoid alveolar renal cell carcinoma. , 2016, F1000Research.